Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Maas

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Translational Andrology and Urology|August 9, 2019
Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?Moritz Maas, Arnulf Stenzl
European Urology|April 25, 2021
Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaJens Bedke, Moritz Maas
European Urology Focus|October 11, 2022
Radical Transurethral Resection of Bladder Tumor in Seemingly Organ-confined Muscle-invasive Bladder Cancer: ConMoritz Maas, Peter C Black
Nature Reviews. Urology|May 24, 2023
Urine biomarkers in bladder cancer - current status and future perspectivesMoritz Maas, Tilman Todenhöfer, Peter C Black
The World Journal of Men'S Health|May 14, 2019
Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based ReviewSimon Walz, Moritz Maas, Arnulf Stenzl, et al.
Aktuelle Urologie|January 26, 2026
[Localised Urothelial Carcinoma of the Upper Urinary Tract: Histopathology, Molecular Genetics, and Clinical Features]Veronika Bahlinger, Moritz Maas, Christian Bolenz, et al.
World Journal of Urology|October 5, 2018
Can urinary biomarkers replace cystoscopy?Moritz Maas, Jens Bedke, Arnulf Stenzl, et al.
Expert Opinion on Biological Therapy|December 16, 2020
Enfortumab vedotin - next game-changer in urothelial cancerMoritz Maas, Viktoria Stühler, Simon Walz, et al.
Expert Opinion on Biological Therapy|October 8, 2019
Immune checkpoint inhibition for the treatment of renal cell carcinomaViktoria Stühler, Jan Moritz Maas, Steffen Rausch, et al.
Expert Opinion on Biological Therapy|May 15, 2020
An evaluation of avelumab for the treatment of genitourinary tumorsViktoria Stühler, Jan Moritz Maas, Simon Walz, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Translational Andrology and Urology|August 9, 2019
Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?Moritz Maas, Arnulf Stenzl
European Urology|April 25, 2021
Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaJens Bedke, Moritz Maas
European Urology Focus|October 11, 2022
Radical Transurethral Resection of Bladder Tumor in Seemingly Organ-confined Muscle-invasive Bladder Cancer: ConMoritz Maas, Peter C Black
Nature Reviews. Urology|May 24, 2023
Urine biomarkers in bladder cancer - current status and future perspectivesMoritz Maas, Tilman Todenhöfer, Peter C Black
The World Journal of Men'S Health|May 14, 2019
Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based ReviewSimon Walz, Moritz Maas, Arnulf Stenzl, et al.
Aktuelle Urologie|January 26, 2026
[Localised Urothelial Carcinoma of the Upper Urinary Tract: Histopathology, Molecular Genetics, and Clinical Features]Veronika Bahlinger, Moritz Maas, Christian Bolenz, et al.
World Journal of Urology|October 5, 2018
Can urinary biomarkers replace cystoscopy?Moritz Maas, Jens Bedke, Arnulf Stenzl, et al.
Expert Opinion on Biological Therapy|December 16, 2020
Enfortumab vedotin - next game-changer in urothelial cancerMoritz Maas, Viktoria Stühler, Simon Walz, et al.
Expert Opinion on Biological Therapy|October 8, 2019
Immune checkpoint inhibition for the treatment of renal cell carcinomaViktoria Stühler, Jan Moritz Maas, Steffen Rausch, et al.
Expert Opinion on Biological Therapy|May 15, 2020
An evaluation of avelumab for the treatment of genitourinary tumorsViktoria Stühler, Jan Moritz Maas, Simon Walz, et al.
Pageof 4